TITLE

Tamoxifen and CYP2D6 Inhibitors

PUB. DATE
September 2009
SOURCE
Travel Medicine Advisor;Sep2009 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reveals the results of two studies on the potential serious drug interaction between tamoxifen and some commonly used selective serotonin reuptake inhibitor (SSRI) anti depressants. According to the studies, some SSRIs particularly paroxetene and fluxetine are potent inhibitors of CYP2D6, the main enzyme responsible for conversion of tamoxifen in its active form. The study revealed conflicting results but it also suggested a near doubling of breast cancer recurrence when tamoxifen was administered with CYP2D6 inhibitors.
ACCESSION #
43828762

 

Related Articles

  • Tamoxifen, SSRIs, and Breast Cancer Recurrence. Elliott, William T. // Clinical Oncology Alert;Sep2009 Supplement, p1 

    The article reports that two studies discussed at the American Society of Clinical Oncology (ASCO) focused on the possible serious drug interaction between tamoxifen and selective serotonin reuptake inhibitor (SSRI) antidepressants. One of the studies claimed that intake of tamoxifen with a...

  • Drug interaction between tamoxifen and antidepressants.  // Australian Prescriber;Feb2011, Vol. 34 Issue 1, p23 

    A recent study has suggested a higher death rate amongst women taking tamoxifen for breast cancer who were also using the selective serotonin reuptake inhibitor paroxetine. This is thought to be a result of reduced conversion by cytochrome P450 2D6 of tamoxifen to a major active metabolite....

  • Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. Kelly, Catherine M.; Juurlink, David N.; Tomes, Tara; Minh Duong-Hua; Pritchard, Kathleen I.; Austin, Peter C.; Paszat, Lawrence F. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/13/2010, Vol. 340 Issue 7742, p355 

    The article discusses a study which examined the influence of selective serotonin reuptake inhibitor (SSRI) antidepressants on the effectiveness of tamoxifen in breast cancer treatment. Tamoxifen is considered as an important part of endocrine breast cancer treatment. The study included 2,430...

  • SSRI use with tamoxifen.  // Primary Care Reports;Apr2010 Pharmacology Watch, p1 

    The article discusses research on selective serotonin reuptake inhibitors (SSRIs) paroxetine (Paxil), an anti-depressant drug that lessens the effect of tamoxifen in women with breast cancer. It references a study published in the "British Medical Journal," wherein the researchers observed more...

  • Tamoxifen, Antidepressants, and CYP2D6: The Conundrum Continues. Holzman, David // JNCI: Journal of the National Cancer Institute;10/21/2009, Vol. 101 Issue 20, p1370 

    The article reports the ambiguities of studies on tamoxifen, antidepressants and CYP2D6. It states that a group of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) impedes with breast cancer drug tamoxifen by preventing the enzyme CYP2D6. Studies at the American Society...

  • Tamoxifen, SSRIs, and Breast Cancer Recurrence.  // Clinical Cardiology Alert;Sep2009 Pharmacology Watch, p1 

    The article discusses research on the drug interaction between tamoxifen and selective serotonin reuptake inhibitors (SSRI) antidepressants. It references two studies published in the "Journal of Clinical Oncology." One of the studies suggested that the risk of breast cancer recurrence is...

  • Interaction of serotonin reuptake inhibitors with tamoxifen. Andersohn, Frank; Willich, Stefan N. // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;2/13/2010, Vol. 340 Issue 7742, p324 

    The authors discuss a study by C. M. Kelly and colleagues which examined the interaction between selective serotonin reuptake inhibitors (SSRI) and tamoxifen in patients with breast cancer. The study found that the risk of breast cancer-related death has increased in women receiving tamoxifen...

  • Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch. Binkhorst, Lisette; Bannink, Marjolein; Bruijn, Peter; Ruit, Jan; Droogendijk, Helga; Alphen, Robbert; Boer, Tilly; Lam, Mei; Jager, Agnes; Gelder, Teun; Mathijssen, Ron; de Bruijn, Peter; van Alphen, Robbert J; den Boer, Tilly D; Lam, Mei Ho; van Gelder, Teun; Mathijssen, Ron H J // Clinical Pharmacokinetics;Feb2016, Vol. 55 Issue 2, p249 

    Background and Objective: The anti-oestrogen tamoxifen requires metabolic activation to endoxifen by cytochrome P450 (CYP) enzymes, predominantly CYP2D6. Potent CYP2D6-inhibiting antidepressants can seriously disrupt tamoxifen metabolism, probably influencing the efficacy of...

  • SSRI use with tamoxifen. Elliott, William T. // Clinical Cardiology Alert;Apr2010 Pharmacology Watch, p1 

    The article discusses research being done on the effect of selective serotonin reuptake inhibitor (SSRI) paroxetine with tamoxifen on women with breast cancer. It references a study published in the "British Medical Journal." The study included more than 2,400 women based in Ontario who were...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics